Compare Heron Therapeutics Inc (HRTX) vs ZIM Integrated Shipping Services Ltd (ZIM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs ZIM Integrated Shipping Services Ltd — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while ZIM Integrated Shipping Services Ltd trades at $30.07 (market cap $3.65B). The key difference: ZIM Integrated Shipping Services Ltd is far larger — about 53.7× Heron Therapeutics Inc's market cap, and ZIM Integrated Shipping Services Ltd pays a 20.16% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and ZIM Integrated Shipping Services Ltd for 27 Days on average.
| HRTX | ZIM | |
|---|---|---|
Market Cap | $68.01M | $3.65B |
Volume | 1,891,941 | 1,068,475 |
Sector | Health | Industrials |
52-Week High | $1.49 | $30.51 |
52-Week Low | $0.27 | $12.44 |
Typical Hold Time | 35 Days | 27 Days |
Enterprise Value | $174.75M | $7.32B |
Dividend Yield | — | 20.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
ZIM Integrated Shipping Services trades at $30.31, up 1.07% with a bullish technical signal from moving averages. The stock shows mixed fundamentals with declining revenue from $6.9B in 2025 to $6.4B in 2026 and net income dropping from $479M to $139M, though Q2 2026 earnings beat expectations. Recent news highlights a potential $35 per share acquisition offer from Hapag-Lloyd pending Israeli government approval, creating significant uncertainty.
The investment outlook balances acquisition upside against operational challenges. While valuation metrics appear reasonable (P/E 26.31, P/S 0.57), declining profitability and the uncertain merger outcome present substantial risk. Analyst sentiment remains cautious with no buy ratings, reflecting concerns about the company's standalone prospects if the acquisition fails to materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About ZIM Integrated Shipping Services Ltd
ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →
